FILING ANALYSIS · THURSDAY, NOVEMBER 5
Akebia Therapeutics, Inc. AKBA — 8-K: Results of Operations and Financial Condition
neutral
Akebia Therapeutics reported Q3 2026 financial results with Vafseo net product revenues of $14.8 million and approximately 11,500 patients on therapy, along with positive VOICE and VOCAL data, but the stock's reaction will depend on how these results compare to expectations
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →